Clinical Trials Directory

Trials / Completed

CompletedNCT06746064

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Inhaled CHF10073 After Single and Multiple Doses in Healthy Volunteers and the Effect of Itraconazole on CHF10073 Exposure

A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of CHF10073 After Single and Multiple Ascending Doses in Healthy Volunteers Via Inhalation and the Effect of Multiple Doses of Itraconazole on CHF10073 Exposure

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
155 (actual)
Sponsor
Chiesi Farmaceutici S.p.A. · Industry
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

The objective of this study is to assess the safety and tolerability of single ascending doses of inhaled CHF10073 (Part 1 of the study) and multiple ascending doses of CHF10073 (Part 2 of the study). The study will also evaluate the PK profile of study drug in plasma and urine after single and repeated administrations of CHF10073. In addition, this study will also investigate the metabolites profile of CHF10073 in plasma, urine and faeces (Part 2 of the study) and the PK profile of CHF10073 in the lungs after bronchoalveolar lavage (BAL) (Part 3 of the study). In addition, the effect of multiple doses of itraconazole on the pharmacokinetic profile of CHF10073 will be investigated (Part 4 of the study).

Conditions

Interventions

TypeNameDescription
DRUGCHF10073 (Part 1 - SAD)Single doses of CHF10073 for each cohort
DRUGPlacebo (Part 1 - SAD)Single doses of placebo matching CHF10073 for each cohort
DRUGCHF10073 (Part 2 - MAD)Multiple doses of CHF10073 for each cohort
DRUGCHF10073 (Part 3)Single dose of CHF10073
DRUGPlacebo (Part 2 - MAD)Multiple doses of placebo matching CHF10073 for each cohort
DRUGitraconazole (Part 4)Multiple dose of itraconazole in treatment period 2
DRUGCHF10073 (Part 4)Single dose of CHF10073 in Treatment Period 1 and 2

Timeline

Start date
2025-01-13
Primary completion
2026-02-04
Completion
2026-02-04
First posted
2024-12-24
Last updated
2026-02-12

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT06746064. Inclusion in this directory is not an endorsement.